FDA is hoping its biosimilar product development phase, where it will offer many opportunities for agency interaction, will make the pathway more attractive to sponsors than a conventional biologic application.
Among the early dilemmas biosimilar sponsors face is whether to engage the abbreviated approval mechanism, the 351(k) path, or file a conventional biologic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?